153 related articles for article (PubMed ID: 37355734)
1. CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition.
Diamond EL; Francis JH; Lacouture ME; Rotemberg V; Yabe M; Petrova-Drus K; Ulaner GA; Reddy R; Abdel-Wahab O; Durham BH
Leukemia; 2023 Aug; 37(8):1737-1740. PubMed ID: 37355734
[No Abstract] [Full Text] [Related]
2. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.
Durham BH; Lopez Rodrigo E; Picarsic J; Abramson D; Rotemberg V; De Munck S; Pannecoucke E; Lu SX; Pastore A; Yoshimi A; Mandelker D; Ceyhan-Birsoy O; Ulaner GA; Walsh M; Yabe M; Petrova-Drus K; Arcila ME; Ladanyi M; Solit DB; Berger MF; Hyman DM; Lacouture ME; Erickson C; Saganty R; Ki M; Dunkel IJ; Santa-María López V; Mora J; Haroche J; Emile JF; Decaux O; Geissmann F; Savvides SN; Drilon A; Diamond EL; Abdel-Wahab O
Nat Med; 2019 Dec; 25(12):1839-1842. PubMed ID: 31768065
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of MEK inhibition in patients with histiocytic neoplasms.
Diamond EL; Durham BH; Ulaner GA; Drill E; Buthorn J; Ki M; Bitner L; Cho H; Young RJ; Francis JH; Rampal R; Lacouture M; Brody LA; Ozkaya N; Dogan A; Rosen N; Iasonos A; Abdel-Wahab O; Hyman DM
Nature; 2019 Mar; 567(7749):521-524. PubMed ID: 30867592
[TBL] [Abstract][Full Text] [Related]
4. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinases as targets for cancer therapy.
Krause DS; Van Etten RA
N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887
[No Abstract] [Full Text] [Related]
6. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases.
Toffalini F; Demoulin JB
Blood; 2010 Oct; 116(14):2429-37. PubMed ID: 20581310
[TBL] [Abstract][Full Text] [Related]
7. CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
Belizaire R; Koochaki SHJ; Udeshi ND; Vedder A; Sun L; Svinkina T; Hartigan C; McConkey M; Kovalcik V; Bizuayehu A; Stanclift C; Schenone M; Carr SA; Padron E; Ebert BL
Blood; 2021 Apr; 137(16):2209-2220. PubMed ID: 33512474
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib regulates
Sun Q; Wu B; Meng F; Yao Q; Huang Z; Xu J; Zhu Z
Hematology; 2023 Dec; 28(1):2204620. PubMed ID: 37199372
[TBL] [Abstract][Full Text] [Related]
9. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
Yamamoto Y; Kiyoi H; Nakano Y; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Saito K; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Saito H; Ueda R; Ohno R; Naoe T
Blood; 2001 Apr; 97(8):2434-9. PubMed ID: 11290608
[TBL] [Abstract][Full Text] [Related]
10. Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders.
Nelson KN; Peiris MN; Meyer AN; Siari A; Donoghue DJ
Trends Mol Med; 2017 Jan; 23(1):59-79. PubMed ID: 27988109
[TBL] [Abstract][Full Text] [Related]
11. Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016.
Tzankov A; Kremer M; Leguit R; Orazi A; van der Walt J; Gianelli U; Hebeda KM
Ann Hematol; 2018 Nov; 97(11):2117-2128. PubMed ID: 30084011
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
Taylor J; Pavlick D; Yoshimi A; Marcelus C; Chung SS; Hechtman JF; Benayed R; Cocco E; Durham BH; Bitner L; Inoue D; Chung YR; Mullaney K; Watts JM; Diamond EL; Albacker LA; Mughal TI; Ebata K; Tuch BB; Ku N; Scaltriti M; Roshal M; Arcila M; Ali S; Hyman DM; Park JH; Abdel-Wahab O
J Clin Invest; 2018 Aug; 128(9):3819-3825. PubMed ID: 29920189
[TBL] [Abstract][Full Text] [Related]
13. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors.
Makishima H; Sugimoto Y; Szpurka H; Clemente MJ; Ng KP; Muramatsu H; O'Keefe C; Saunthararajah Y; Maciejewski JP
Leukemia; 2012 Jul; 26(7):1547-54. PubMed ID: 22246246
[TBL] [Abstract][Full Text] [Related]
14. A novel GAB2::BRAF fusion in cutaneous non-Langerhans-cell histiocytosis with systemic involvement.
Wu B; Konnick EQ; Kimble EL; Hendrie PC; Shinohara MM; Moshiri AS
J Cutan Pathol; 2022 Aug; 49(8):727-730. PubMed ID: 35332933
[TBL] [Abstract][Full Text] [Related]
15. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.
Shih LY; Liang DC; Huang CF; Chang YT; Lai CL; Lin TH; Yang CP; Hung IJ; Liu HC; Jaing TH; Wang LY; Yeh TC
Leukemia; 2008 Feb; 22(2):303-7. PubMed ID: 17960171
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia.
Casas S; Nagy B; Elonen E; Aventín A; Larramendy ML; Sierra J; Ruutu T; Knuutila S
Leuk Lymphoma; 2003 Nov; 44(11):1935-41. PubMed ID: 14738146
[TBL] [Abstract][Full Text] [Related]
17. Histiocytic sarcoma that mimics benign histiocytosis.
Boisseau-Garsaud AM; Vergier B; Beylot-Barry M; Nastasel-Menini F; Dubus P; de Mascarel A; Eghbali H; Beylot C
J Cutan Pathol; 1996 Jun; 23(3):275-82. PubMed ID: 8793665
[TBL] [Abstract][Full Text] [Related]
18. Multisystem ALK-positive histiocytosis: a multi-case study and literature review.
Liu W; Liu HJ; Wang WY; Tang Y; Zhao S; Zhang WY; Yan JQ; Liu WP
Orphanet J Rare Dis; 2023 Mar; 18(1):53. PubMed ID: 36915094
[TBL] [Abstract][Full Text] [Related]
19. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.
Ikezoe T; Nishioka C; Tasaka T; Yang Y; Komatsu N; Togitani K; Koeffler HP; Taguchi H
Mol Cancer Ther; 2006 Oct; 5(10):2522-30. PubMed ID: 17041096
[TBL] [Abstract][Full Text] [Related]
20. CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia.
Gioia R; Trégoat C; Dumas PY; Lagarde V; Prouzet-Mauléon V; Desplat V; Sirvent A; Praloran V; Lippert E; Villacreces A; Leconet W; Robert B; Vigon I; Roche S; Mahon FX; Pasquet JM
J Pathol; 2015 Sep; 237(1):14-24. PubMed ID: 25965880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
